Schedule your personal consultation with Dr
As of 2026, with improved regulatory clarity and access through licensed providers, these peptides are becoming more structured, safer, and clinically accessible but should always be used under professional guidance.
But anyway, it was one of the earlier ones
(2024) CNS Neuroscience & Therapeutics , 30(3): e14676 Confirmed ARA-290 provides neuroprotection in a mouse MCAO cerebral ischaemia model via CR, significantly reducing neuronal apoptosis and inflammatory cytokines, equivalent to EPO neuroprotection but without erythropoietic side effects
The anti-obesity effects were confirmed in several clinical trials performed (3)
Solutions for Poor Sleep with GLOW Peptide Therapy: By addressing root causes such as systemic inflammation and supporting the body's repair processes, the GLOW Peptide protocol can indirectly improve sleep